학술논문
Comparative in vitro and in vivo Evaluation of Different Iron Oxide-Based Contrast Agents to Promote Clinical Translation in Compliance with Patient Safety
ORIGINAL RESEARCH
ORIGINAL RESEARCH
Document Type
Academic Journal
Author
Source
International Journal of Nanomedicine. April 30, 2023, Vol. 18, p2071, 16 p.
Subject
Language
English
ISSN
1178-2013
Abstract
Introduction Imaging the structure and function of tissues and organs is often the key to reliable medical diagnosis and a prerequisite for effective treatment. One of the most important imaging [...]
Introduction: One of the major challenges in the clinical translation of nanoparticles is the development of formulations combining favorable efficacy and optimal safety. In the past, iron oxide nanoparticles have been introduced as an alternative for gadoliniumcontaining contrast agents; however, candidates available at the time were not free from adverse effects. Methods: Following the development of a potent iron oxide-based contrast agent SPIO[N.sup.Dex], we now performed a systematic comparison of this formulation with the conventional contrast agent ferucarbotran and with ferumoxytol, taking into consideration their physicochemical characteristics, bio- and hemocompatibility in vitro and in vivo, as well as their liver imaging properties in rats. Results: The results demonstrated superior in vitro cyto-, hemo- and immunocompatibility of SPIO[N.sup.Dex] in comparison to the other two formulations. Intravenous administration of ferucarbotran or ferumoxytol induced strong complement activation- related pseudoallergy in pigs. In contrast, SPIO[N.sup.Dex] did not elicit any hypersensitivity reactions in the experimental animals. In a rat model, comparable liver imaging properties, but a faster clearance was demonstrated for SPIO[N.sup.Dex]. Conclusion: The results indicate that SPIO[N.sup.Dex] possess an exceptional safety compared to the other two formulations, making them a promising candidate for further clinical translation. Keywords: magnetic resonance imaging, MRI, nanomedicine, nanoparticles, complement activation, CARPA
Introduction: One of the major challenges in the clinical translation of nanoparticles is the development of formulations combining favorable efficacy and optimal safety. In the past, iron oxide nanoparticles have been introduced as an alternative for gadoliniumcontaining contrast agents; however, candidates available at the time were not free from adverse effects. Methods: Following the development of a potent iron oxide-based contrast agent SPIO[N.sup.Dex], we now performed a systematic comparison of this formulation with the conventional contrast agent ferucarbotran and with ferumoxytol, taking into consideration their physicochemical characteristics, bio- and hemocompatibility in vitro and in vivo, as well as their liver imaging properties in rats. Results: The results demonstrated superior in vitro cyto-, hemo- and immunocompatibility of SPIO[N.sup.Dex] in comparison to the other two formulations. Intravenous administration of ferucarbotran or ferumoxytol induced strong complement activation- related pseudoallergy in pigs. In contrast, SPIO[N.sup.Dex] did not elicit any hypersensitivity reactions in the experimental animals. In a rat model, comparable liver imaging properties, but a faster clearance was demonstrated for SPIO[N.sup.Dex]. Conclusion: The results indicate that SPIO[N.sup.Dex] possess an exceptional safety compared to the other two formulations, making them a promising candidate for further clinical translation. Keywords: magnetic resonance imaging, MRI, nanomedicine, nanoparticles, complement activation, CARPA